CMXC Announces Results of Preliminary Analysis of Metabolomic Assays
News Feb 27, 2015
Cell MedX Corp. has announced that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Its main objective was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending.
Analysis of this early data set indicates substantial changes in at least two key pathways that would correlate with improvements in glucose and lipid metabolism. These findings will inform further experimentation, including the Phase 1B clinical trial, which begins recruiting in March 2015.
The analysis of the samples was conducted by The Metabolomics Innovation Centre at the University of Alberta (“TMIC”), whose analytic and informatics toolsets and translational “omics” expertise allows for cost-effective and more accurate results of assays.
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE
£2.2M Collaboration to Fuel Drug Developments for HIVNews
A collaboration between the University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) has been awarded a further £2.2M ($3M) to develop sophisticated new medicines for HIV.READ MORE
Antibody Treatment Effective in Treatment-Resistant COPD PatientsNews
The new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD.READ MORE